{"id":3871,"date":"2021-02-11T18:32:30","date_gmt":"2021-02-12T02:32:30","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=3871"},"modified":"2021-02-11T18:32:30","modified_gmt":"2021-02-12T02:32:30","slug":"sars-cov-2-antibody-prevalence-in-england-following-the-first-peak-of-the-pandemic","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/02\/11\/sars-cov-2-antibody-prevalence-in-england-following-the-first-peak-of-the-pandemic\/","title":{"rendered":"SARS-CoV-2 Antibody Prevalence in England Following the First Peak of the Pandemic"},"content":{"rendered":"<p>A large serosurvey in England (REACT-2 Study) estimated the nationwide seroprevalence of SARS-CoV-2 to be 6%, corresponding to an estimated 3.4 million people with prior infection. Seroprevalence was determined from a representative cohort of over 100,000 adults (&gt;18 years old). Prevalence was 2- to 3-fold higher among healthcare workers compared with non-essential workers, and higher among Black or South Asian adults compared to white adults, although age- and sex-specific infection fatality ratios were similar across ethnicities.<\/p>\n<p><i>Ward et al. (Feb 10, 2021). SARS-CoV-2 Antibody Prevalence in England Following the First Peak of the Pandemic. Nature Communications. <\/i><a href=\"https:\/\/doi.org\/10.1038\/s41467-021-21237-w\">https:\/\/doi.org\/10.1038\/s41467-021-21237-w<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A large serosurvey in England (REACT-2 Study) estimated the nationwide seroprevalence of SARS-CoV-2 to be 6%, corresponding to an estimated 3.4 million people with prior infection. Seroprevalence was determined from a representative cohort of over 100,000 adults (&gt;18 years old). Prevalence was 2- to 3-fold higher among healthcare workers compared with non-essential workers, and higher&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/02\/11\/sars-cov-2-antibody-prevalence-in-england-following-the-first-peak-of-the-pandemic\/\">Read more<\/a><\/div>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[32,27],"topic":[19],"class_list":["post-3871","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-immunity","tag-testing","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/3871","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=3871"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/3871\/revisions"}],"predecessor-version":[{"id":3872,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/3871\/revisions\/3872"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=3871"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=3871"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=3871"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=3871"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}